Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind dose-response study of vitamin D3 in CKD stage 3 with secondary hyperparathyroidism
2019-000640-10Phase 2Completed
- Sponsor
- SMB Laboratoires
- Start
- Jul 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vitamin d in chronic kidney disease (CKD), secondary hyperparathyroidism (SHPT) and Vitamin D deficiency (VDD) (4 arms), sponsored by SMB Laboratoires. Primary endpoint: Change in intact parathyroid hormone at week 12. Started Jul 2019; status: completed.
02
Drugs
vitamin d
03
Conditions
chronic kidney disease (CKD)secondary hyperparathyroidism (SHPT)Vitamin D deficiency (VDD)
Beyond the preview
Go deeper on 2019-000640-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000640-10.